Atrial Natriuretic Peptide

Spatial Structure of ANP

Schematic Represenatation of ANP Peptide Precursor for Human & Rat
ANP (Human) Precursor Sequence

ANP Sequence Comparison

Four cardiac peptide hormones, i.e., vessel dilator, long acting natriuretic peptide (LANP), kaliuretic peptide, and atrial natriuretic peptide (ANP) synthesized by the same gene decrease within 24 hours up to 97% the number of human breast, colon, pancreatic, and prostate adenocarcinoma cells as well as human small-cell and squamous carcinomas of the lung cells. These peptide hormones completely inhibit the growth of human pancreatic adenocarcinomas growing in athymic mice. Immunocytochemical investigations have revealed that LANP, vessel dilator, kaliuretic peptide and ANP localize to the nucleus and cytoplasm of human pancreatic adenocarcinomas, which is consistent with their ability to decrease DNA synthesis in the nucleus of this cancer mediated by the intracellular messenger cyclic GMP. These peptide hormones also localize to the endothelium of capillaries and fibroblasts within these cancers. These are the first growth-inhibiting peptide hormones ever demonstrated to localize to the nucleus. Their ability to decrease the activation of growth promoting substances such as Extracellular Receptor Kinase (ERK)-1/2 and Nuclear Factor Kappa Beta (NFkappaB) suggests that in addition to inhibiting DNA synthesis their ability to decrease the activation of growth promoting substances helps to mediate their ability to inhibit the growth of human cancers.

Saba SR, Vesely DL. Cardiac natriuretic peptides: hormones with anticancer effects that localize to nucleus, cytoplasm, endothelium, and fibroblasts of human cancers. Histol Histopathol. 2006;21(7):775-83.

Atrial natriuretic peptides (ANPs) are a family of peptide hormones, e.g., ANP, long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide synthesized by the ANP gene. Brain natriuretic peptide (BNP) and C-type natriuretic peptide are also members of this family but are synthesized by separate genes. Within the kidney, the ANP prohormone's posttranslational processing is different from that of other tissues, resulting in an additional four amino acids added to the NH2 terminus of ANP (e.g., urodilatin). Each of these natriuretic and diuretic peptides increases within the circulation with acute renal failure (ARF). Renal transplantation but not hemodialysis returns their circulating concentrations to those of healthy individuals. BNP and adrenomedullin, a 52-amino acid natriuretic peptide, have beneficial effects on glomerular hypertrophy and glomerular injury but do not improve tubular injury (i.e., acute tubular necrosis). Vessel dilator ameliorates acute tubular necrosis with regeneration of the brush borders of proximal tubules. Vessel dilator decreases mortality in ARF from 88 to 14% at day 6 of ARF, even when given 2 days after renal failure has been established.

Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol. 2003;285(2):F167-77.

Atrial natriuretic peptide (ANP), atrial natriuretic factor (ANF), atrial natriuretic hormone (ANH), or atriopeptin, is a powerful vasodilator, and a polypeptide hormone secreted by heart muscle cells. It is involved in the homeostatic control of body water, sodium, potassium and fat (adipose tissue). It is released by muscle cells in the upper chambers (atria) of the heart (atrial myocytes) in response to high blood pressure. ANP acts to reduce the water, sodium and adipose loads on the circulatory system, thereby reducing blood pressure.

ANP is a 28-amino acid peptide with a 17-amino acid ring in the middle of the molecule. The ring is formed by a disulfide bond between two cysteine residues at positions 7 and 23. ANP is closely related to BNP (brain natriuretic peptide) and CNP (C-type natriuretic peptide), which all share the same amino acid ring. ANP was discovered in 1981 by a team in Kingston, Ontario, Canada after they made the seminal observation that injection of atrial (but not ventricular) tissue extracts into rats caused copious natriuresis. 

Spatial Structure of ANP
ANP is produced, stored and released by cardiac myocytes of the atria of the heart. It is released in response to atrial stretch and a variety of other signals induced by hypervolemia, exercise or caloric restriction. The hormone is constitutively expressed in the ventricle in response to stress induced by increased afterload (e.g. increased ventricular pressure from aortic stenosis) or injury (e.g. myocardial infarction).
ANP is secreted in response to:

  • Atrial distention, stretching of the vessel walls
  • Sympathetic stimulation of β-adrenoceptors 
  • Raised sodium concentration (hypernatremia), though sodium concentration is not the direct stimulus for increased ANP secretion 
  • Angiotensin-II 
  • Endothelin, a potent vasoconstrictor 
The atria become distended by high extracellular fluid and blood volume, and atrial fibrillation. Notably, ANP secretion increases in response to immersion of the body in water, which causes atrial stretch due to an altered distribution of intravascular fluid. ANP secretion in response to exercise has also been demonstrated in horses.


anp Structure ANP sequence among species

Four peptide hormones [e.g., atrial natriuretic peptide (ANP), long-acting natriuretic peptide (LANP), vessel dilator, and kaliuretic peptide] are synthesized by this gene. Each of these peptide hormones has biological effects, e.g., natriuresis and diuresis, mediated via the kidney. LANH, long-acting natriuretic hormone (a different nomenclature for LANP); a.a., amino acids.

Related Products

Catalog# Product Standard Size Price
005-24 ANP (Rat, Mouse) 200 µg $97
005-06 ANP, alpha (1-28) (Human, Porcine, Ovine, Canine) 200 µg $97
EKE-005-06 ANP, alpha (1-28) (Human, Porcine, Ovine, Canine) - Extraction-Free EIA Kit 96 wells $520
FC5-005-06 ANP, alpha (1-28) (Human, Porcine, Ovine, Canine) - Cy5 Labeled 1 nmol $408
FEK-005-24 ANP (Rat, Mouse) - Fluorescent EIA Kit 96 wells $500
EK-005-06 ANP, alpha (1-28) (Human, Porcine, Ovine, Canine) - EIA Kit 96 wells $458
EK-005-24 ANP (Rat, Mouse) - EIA Kit 96 wells $458
G-005-18 ANP (95-126) / Urodilatin (Human) - Purified IgG Antibody 400 µg $332
B-005-07 ANP, alpha (1-28) (Human, Porcine, Ovine, Canine) - Biotin Labeled 100 µg $255
T-005-06 ANP, alpha (1-28) (Human, Porcine, Ovine, Canine) - I-125 Labeled 10 µCi $723
B-005-24 ANP (Rat, Mouse) - Biotin Labeled 100 µg $255
RK-005-24 ANP (Rat, Mouse) - RIA Kit 125 tubes $588
005-15 ANP 100 µg $204
005-18 ANP (95-126) / Urodilatin (Human) 200 µg $133
RK-005-19 ANP (26-55) / Leucine-Rich Acidic Nuclear Protein (LANP) (26-55) (Human) - RIA Kit 125 tubes $619
H-005-24 ANP (Rat, Mouse) - Antibody 50 µl $179
005-28 ANP (8-33) (Rat) 200 µg $66
RK-005-06 ANP, alpha (1-28) (Human, Porcine, Ovine, Canine) - RIA Kit 125 tubes $588
005-20 ANP (56-92) (Human) 200 µg $163
005-26 ANP (4-23) amide (Rat) 200 µg $97
005-19 ANP (26-55) / Leucine-Rich Acidic Nuclear Protein (LANP) (26-55) (Human) 200 µg $138
005-22 ANP (104-123) (Human) 200 µg $77
H-005-06 ANP, alpha (1-28) (Human, Porcine, Ovine, Canine) - Antibody 50 µl $179
EK-005-06CE ANP, alpha (1-28) (Human, Porcine, Ovine, Canine) - EIA Kit, CE Mark Certified 96 wells $478
005-21 ANP (104-116) (Human) 200 µg $56
005-23 ANP (104-116) (Human) 100 µg $270
H-005-21 ANP (104-116) (Human) - Antibody 50 µl $179
T-005-23 ANP (104-116) (Human) - I-125 Labeled 10 µCi $723
T-G-005-21 ANP (104-116) (Human) - I-125 Labeled Purified IgG 10 µCi $723
G-005-21 ANP (104-116) (Human) - Purified IgG Antibody 400 µg $332

1 2 3 4 Next